Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI‐daily diary

Abstract

Common symptoms of gastroparesis include nausea, vomiting, early satiety, postprandial fullness, and upper abdominal pain. Domperidone is used for treatment of gastroparesis. Daily symptom scoring may help document efficacy. Aim:To determine the effectiveness of domperidone for gastroparesis symptoms using the gastroparesis cardinal symptom index-daily diary (GCSI-DD) and to determine which symptoms improve and when with domperidone treatment.Methods: Symptomatic patients with diabetic or idiopathic gastroparesis were enrolled. Gastric emptying was performed using 4 hour scintigraphy. GCSI-DD recorded symptoms at baseline and during six weeks of treatment with domperidone 10 mg TID. GCSI-DD records severity of nausea, early satiety, postprandial fullness, upper abdominal pain, overall gastroparesis symptoms on a scale of 0 (no symptom) to 4 (very severe) and records the number of vomiting episodes per day.

The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis

“…The ANMS GCSI‐DD core symptom score was defined as the average of the five gastroparesis symptoms (nausea, early satiety, postprandial fullness, upper abdominal pain, and vomiting), and the ANMS GCSI‐DD endpoint composite score was defined as the average of the four gastroparesis severity items (nausea, early satiety, postprandial fullness, and upper abdominal pain). These two scores were assessed as prior studies have not established a consensus as to whether adding vomiting frequency helped improve the performance characteristics of the score …”

“…These two scores were assessed as prior studies have not established a consensus as to whether adding vomiting frequency helped improve the performance characteristics of the score. 32 Baseline sociodemographic and clinical characteristics were generated using descriptive statistics (frequency, percent, mean, median, standard deviation [SD], and range). Weekly ANMS GCSI-DD core symptom, endpoint composite, and individual item scores were summarized using Day 1 to Day 7 data to examine baseline instrument characteristics, including an assessment of floor and ceiling effects (>25% having the minimum or maximum response, respectively).…”

A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research

“… 1 Justin-Besancon and Laville, 1964 ; 2 Sanger, 2009 ; 3 Camilleri et al, 2013 ; 4 Briejer et al, 1995 ; 5 Smith et al, 2008 ; 6 Johnston et al, 2014 ; 7 Creytens, 1984 ; 8 Bergeron and Blier, 1994 ; 9 Sanger et al, 2013 ; 10 Miner et al, 1987 ; 11 Peeters et al, 1989 ; 12 Sanger et al, 2013 ; 13 Broad et al, 2012 ; 14 Broad and Sanger, 2013 ; 15 Javid et al, 2013 ; 16 Marrinan et al, 2018 ; 17 Sanger and Alpers, 2008 ; 18 Janssen et al, 2013 ; 19 Champion et al, 1986 ; 20 Ahmad et al, 2006 ; 21 Heckert and Parkman, 2018 ; 22 Markey and Shafat, 2012 ; 23 McFarlane et al, 2018 ; 24 Sanger, 1985c ; 25 Ortiz et al, 2015 ; 26 Midani and Parkman, 2016 ; 27 Pasricha et al, 2016 ; 28 Kojima et al, 1999 ; 29 Sanger and Furness, 2016 ; 30 Broad et al, 2014 ; 31 Camilleri and Acosta, 2015 ; 32 Koch, 2014 ; 33 O'Grady et al, 2012 ; 34 Angeli et al, 2015 ; 35 Sanger and Pasricha, 2017 . …”

Diabetic gastroparesis: current challenges and future prospects

“… 56 Similarly, a recent prospective cohort of 34 patients (5 DMGP and 29 IDGP) taking domperidone at 10 mg TID for an average treatment duration of 36.9 days showed an overall GP symptom improvement ( p <0.05). 48 In a systematic review of 28 trials (11 full articles and 17 abstracts), 64% of studies showed a symptom improvement, 60% showed an improvement in GE, and 67% of studies showed a reduction in hospital readmissions. It was concluded that there is level 3 evidence for the efficacy of domperidone in DMGP, leading to a grade C recommendation.…”